BACKGROUND: To report the outcomes of patients with locoregionally advanced and high- risk salivary gland malignancies treated with surgery followed by adjuvant chemoradiotherapy. METHODS: From 09/1991 - 06/2007, 24 high-risk salivary gland cancer patients were treated with surgery, followed by adjuvant chemoradiotherapy for high-risk pathologic features including, perineural involvement, nodal involvement, positive margins, or T3/T4 tumors. Chemoradiotherapy was delivered for 4-6 alternating week cycles: the most common regimen, TFHX, consisted of 5 days paclitaxel (100 mg/m² on d1), infusional 5-fluorouracil (600 mg/m²/d × 5d), hydroxyurea (500 mg PO BID), and 1.5 Gy twice daily irradiation followed by a 9-day break without treatment. RESULTS: Median follow-up was 42 months. The parotid gland was more frequently involved (n = 17) than minor (n = 4) or submandibular (n = 3) glands. The median radiation dose was 65 Gy (range 55-68 Gy). Acute treatment related toxicity included 46% grade 3 mucositis and 33% grade 3 hematologic toxicity. Six patients required feeding tubes during treatment. One patient progressed locally, 8 patients progressed distantly, and none progressed regionally. Five-year locoregional progression free survival was 96%. The 3 and 5 year overall survival was 79% and 59%, respectively. Long-term complications included persistent xerostomia (n = 5), esophageal stricture requiring dilatation (n = 1), and tempromandibular joint syndrome (n = 1). CONCLUSIONS: Surgical resection followed by adjuvant chemoradiotherapy results in promising locoregional control for high-risk salivary malignancy patients.
BACKGROUND: To report the outcomes of patients with locoregionally advanced and high- risk salivary gland malignancies treated with surgery followed by adjuvant chemoradiotherapy. METHODS: From 09/1991 - 06/2007, 24 high-risk salivary gland cancerpatients were treated with surgery, followed by adjuvant chemoradiotherapy for high-risk pathologic features including, perineural involvement, nodal involvement, positive margins, or T3/T4 tumors. Chemoradiotherapy was delivered for 4-6 alternating week cycles: the most common regimen, TFHX, consisted of 5 days paclitaxel (100 mg/m² on d1), infusional 5-fluorouracil (600 mg/m²/d × 5d), hydroxyurea (500 mg PO BID), and 1.5 Gy twice daily irradiation followed by a 9-day break without treatment. RESULTS: Median follow-up was 42 months. The parotid gland was more frequently involved (n = 17) than minor (n = 4) or submandibular (n = 3) glands. The median radiation dose was 65 Gy (range 55-68 Gy). Acute treatment related toxicity included 46% grade 3 mucositis and 33% grade 3 hematologic toxicity. Six patients required feeding tubes during treatment. One patient progressed locally, 8 patients progressed distantly, and none progressed regionally. Five-year locoregional progression free survival was 96%. The 3 and 5 year overall survival was 79% and 59%, respectively. Long-term complications included persistent xerostomia (n = 5), esophageal stricture requiring dilatation (n = 1), and tempromandibular joint syndrome (n = 1). CONCLUSIONS: Surgical resection followed by adjuvant chemoradiotherapy results in promising locoregional control for high-risk salivary malignancypatients.
Authors: Mark Agulnik; Ezra W E Cohen; Roger B Cohen; Eric X Chen; Everett E Vokes; Sebastien J Hotte; Eric Winquist; Scott Laurie; D Neil Hayes; Janet E Dancey; Shirley Brown; Gregory R Pond; Ian Lorimer; Manijeh Daneshmand; James Ho; Ming-Sound Tsao; Lillian L Siu Journal: J Clin Oncol Date: 2007-09-01 Impact factor: 44.544
Authors: Robert Haddad; A Dimitrios Colevas; Jeffrey F Krane; Dennis Cooper; Bonnie Glisson; Philip C Amrein; Linda Weeks; Rosemary Costello; Marshall Posner Journal: Oral Oncol Date: 2003-10 Impact factor: 5.337
Authors: Olga Micol Martínez; Elena Daghoum Dorado; María Dolores Amorós García; María Isabel Oviedo Ramírez; Isabel de la Fuente Muñoz; Jose Luis Fuster Soler Journal: Rare Tumors Date: 2016-10-06
Authors: Brian J Gebhardt; James P Ohr; Robert L Ferris; Umamaheswar Duvvuri; Seungwon Kim; Jonas T Johnson; Dwight E Heron; David A Clump Journal: Am J Clin Oncol Date: 2018-09 Impact factor: 2.339
Authors: Benjamin E Onderdonk; Everett E Vokes; Michael Gwede; Elizabeth Blair; Nishant Agrawal; Daniel J Haraf Journal: Health Sci Rep Date: 2020-10-07
Authors: Sana D Karam; James W Snider; Hongkun Wang; Margaux Wooster; Christopher Lominska; John Deeken; Kenneth Newkirk; Bruce Davidson; K William Harter Journal: Front Oncol Date: 2012-05-31 Impact factor: 6.244
Authors: A D Jensen; M Poulakis; V Vanoni; M Uhl; N Chaudhri; P A Federspil; K Freier; J Krauss; J Debus Journal: Radiat Oncol Date: 2016-07-07 Impact factor: 3.481
Authors: Moses Tam; Nadeem Riaz; Lucas Resende Salgado; Daniel E Spratt; Evangelia Katsoulakis; Alan Ho; Luc G T Morris; Richard Wong; Suzanne Wolden; Shyam Rao; Nancy Lee Journal: J Radiat Oncol Date: 2013-07-10